Sanovas Inc., a life science company accelerating the development and commercialization of next-generation micro-invasive diagnostics, devices and drug delivery technologies, announces that its MicroCam Inc. subsidiary has commenced commercialization of the MicroCam™ System via its OEM partnership with Healthmark Industries, which is launching its new product—Flexible Inspection Scope—this week.
The MicroCam System represents an entirely new concept in medical imaging that has not been possible, until now. The MicroCam System is a highly integrated platform of proprietary micro optics, electronics and software. The 'Plug 'N Play' capabilities of the 3mm-diameter, 5mm-long MicroCam System enable it to be sold as an OEM product as well as a branded MicroCam product, which MicroCam Inc. is pursuing simultaneously with its OEM strategy.
Healthmark Industries Co. is a supplier of infection control and device reprocessing diagnostic systems. The company has incorporated MicroCam units into a new product launching this week, the Flexible Inspection Scope, empowering sterilization processing professionals to be able to literally "see" inside tough-to-clean medical devices such as arthroscopic shavers prior to sterilization, to ensure that they are completely clean.
"Intricate modern instruments have revolutionized surgery, of course. But they are very difficult to clean," says Ralph Basile, vice president of marketing for Healthmark Industries. "The MicroCam lets us inspect with a clarity of image that heretofore was not possible with affordable technology."
"MicroCam is paving the way for a paradigm shift in minimally invasive surgery toward multimodal imaging methods, linearly integrated medical devices, and natural orifice surgery," says Larry Gerrans, co-founder, president and CEO of Sanovas, and inventor of the MicroCam system. "MicroCam's small-diameter 'Plug 'N Play' optics represent a highly disruptive leap in technology, cost and portability. This is a unique platform solution whose time has come. The technology will, most certainly, evolve the interventional capabilities in the existing market and expand the growth of minimally invasive surgery to nearly 3.1 billion patients in the emerging markets."